1. RIO-LIPIDS: Changes from baseline for the end points in the intention-to-treat population
Placebo group
5-mg rimonabant group p
20-mg rimonabant group
Weight (kg)
-1.5
-3.1
<0.001
-6.9
Waist circumference (cm)
-2.4
-3.5
0.029
-7.1
Triglycerides (%)
-0.2
+1.2 NS
-12.6
HDL (%)
+11.0
+14.2
0.025
+19.1
*last-observation-carried-forward analysis
Després JP et al. N Engl J Med 2005; 353:

2. One-year results of sibutramine vs lifestyle-modification counseling
Treatment arm
Mean weight loss (kg)
Sibutramine alone
5.0
Lifestyle modification alone
6.7
Sibutramine plus brief therapy
7.5
Sibutramine plus lengthy counseling
12.1
Wadden TA, et al. N Engl J Med 2005; 353: